On the other hand, it was observed that vaccination with the EPS301-adjuvanted rPcrV significantly enhanced IL-17A compared with other groups in response to an infection both on day 7 and day 112 post vaccination (Figs 4E and S5E). This evidence concerns the gene IL17A and infection.